Abraham I, Chin K V, Gottesman M M, Mayo J K, Sampson K E
Cell Biology Department, Upjohn Company, Kalamazoo, Michigan 49001.
Exp Cell Res. 1990 Jul;189(1):133-41. doi: 10.1016/0014-4827(90)90265-c.
Wild-type Chinese hamster ovary (CHO) cells were transfected with a DNA clone (MT-REV, site A) carrying a mouse gene for a dominant mutant regulatory subunit (RI) gene of cAMP-dependent protein kinase (PKA) from S49 cells along with a marker for G418 resistance. G418-resistant transfectant clone R-2D1 was resistant to 8-Br-cAMP-induced growth inhibition and morphological changes. The cells also did not phosphorylate a 50-kDa protein after cAMP stimulation and had decreased PKA activity, both characteristics of PKA mutants. Northern blot analysis indicated that clone R-2D1 was actively transcribing the MT-REV (site A)-specific RNA. We also tested clone R-2D1 for sensitivity to certain natural product hydrophobic drugs and found increased sensitivity to several drugs including adriamycin. Hypersensitivity to these drugs has previously been shown by us to be a characteristic of a CHO PKA mutant cell line. Expression of the mutant RI gene is also associated with a decrease in expression of the multidrug resistance associated P-glycoprotein (gp170) mRNA and protein. These results show that the PKA mutant RI gene from S49 cells acts as a dominant mutation to reduce the total PKA activity in the CHO transfectants as it does in mouse S49 cells. This study also confirms that reduced PKA activity modulates the basal multidrug resistance of these cells, apparently by causing decreased expression of the mdr gene at the protein and mRNA level.
将携带来自S49细胞的cAMP依赖性蛋白激酶(PKA)显性突变调节亚基(RI)基因的小鼠基因的DNA克隆(MT-REV,位点A)与G418抗性标记一起转染野生型中国仓鼠卵巢(CHO)细胞。G418抗性转染子克隆R-2D1对8-Br-cAMP诱导的生长抑制和形态变化具有抗性。cAMP刺激后,这些细胞也不会使一种50 kDa的蛋白质磷酸化,并且PKA活性降低,这两者都是PKA突变体的特征。Northern印迹分析表明克隆R-2D1正在积极转录MT-REV(位点A)特异性RNA。我们还测试了克隆R-2D1对某些天然产物疏水药物的敏感性,发现其对包括阿霉素在内的几种药物的敏感性增加。我们之前已表明对这些药物的超敏反应是CHO PKA突变细胞系的一个特征。突变RI基因的表达还与多药耐药相关P-糖蛋白(gp170)mRNA和蛋白质表达的降低有关。这些结果表明,来自S49细胞的PKA突变RI基因在CHO转染子中起到显性突变的作用,以降低总PKA活性,就像在小鼠S49细胞中一样。这项研究还证实,降低的PKA活性调节这些细胞的基础多药耐药性,显然是通过在蛋白质和mRNA水平上导致mdr基因表达降低来实现的。